Towa Pharmaceutical Co., Ltd.

OTCPK:TWAP.F Stock Report

Market Cap: US$1.3b

Towa Pharmaceutical Management

Management criteria checks 3/4

Towa Pharmaceutical's CEO is Itsuro Yoshida, appointed in Jun 1996, has a tenure of 30.08 years. total yearly compensation is ¥113.00M, comprised of 62.8% salary and 37.2% bonuses, including company stock and options. directly owns 2.96% of the company’s shares, worth $37.51M. The average tenure of the management team and the board of directors is 2.5 years and 3.1 years respectively.

Key information

Itsuro Yoshida

Chief executive officer

JP¥113.0m

Total compensation

CEO salary percentage62.83%
CEO tenure30.1yrs
CEO ownership3.0%
Management average tenure2.5yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Itsuro Yoshida's remuneration changed compared to Towa Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

JP¥5b

Dec 31 2025n/an/a

JP¥21b

Sep 30 2025n/an/a

JP¥21b

Jun 30 2025n/an/a

JP¥16b

Mar 31 2025JP¥113mJP¥71m

JP¥19b

Compensation vs Market: Itsuro's total compensation ($USD692.58K) is below average for companies of similar size in the US market ($USD5.19M).

Compensation vs Earnings: Insufficient data to compare Itsuro's compensation with company performance.

CEO

Itsuro Yoshida (75 yo)

30.1yrs
Tenure
JP¥113,000,000
Compensation

Mr. Itsuro Yoshida has been the President at Towa Pharmaceutical Co. Ltd. since June 1996. Mr. Yoshida joined Towa Pharmaceutical Co., Ltd.in May 1979 and served as its Manager of Accounting since May 198...

Leadership Team

NamePositionTenureCompensationOwnership
Itsuro Yoshida
President & Representative Director30.1yrsJP¥113.00m2.96%
$ 37.5m
Shiro Hatagami
Operating Officer and GM of Accounting & Finance Division2.5yrsno datano data
Tetsuo Yamashita
Operating Officerno datano datano data
Masaji Morikawa
Operating Officer & Division Manager of Sales and Marketing Divisionno datano datano data
Shigeki Fujita
Operating Officer & GM of Human Resource Development Center2.5yrsno datano data
Yutaka Okuda
Senior Operating Officer & Div Manager of R&D Div and Unit Manager of Innovative Tech Research2.5yrsno datano data
Masao Tanaka
Directorno datano data0.014%
$ 180.4k
Osamu Uchikawa
Executive MD & Director1.1yrsno data0.010%
$ 126.2k
Takahiko Taniguchi
Senior Executive Officer & Head of Quality Assurance Division1.5yrsno datano data
Naomichi Hashizume
Human Resources Division Chiefno datano datano data
Hideshi Nakamura
GM of President’s Officeno datano datano data
Takeshi Sugiura
Executive Officerno datano datano data
2.5yrs
Average Tenure
72yo
Average Age

Experienced Management: TWAP.F's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Itsuro Yoshida
President & Representative Director42.6yrsJP¥113.00m2.96%
$ 37.5m
Masao Tanaka
Director9.1yrsno data0.014%
$ 180.4k
Osamu Uchikawa
Executive MD & Director3.1yrsno data0.010%
$ 126.2k
Hideshi Nakamura
GM of President’s Officeless than a yearno datano data
Masaaki Takeyasu
Director2.1yrsno data0.0073%
$ 92.7k
Nobuki Ando
Independent Outside Director2.1yrsno datano data
Norikazu Eiki
Independent Outside Director11.1yrsno datano data
Muneya Taniguchi
Independent Outside Directorless than a yearno datano data
Kaori Oishi
Independent Outside Director6.1yrsno datano data
Kenryo Goto
Independent Outside Director5.1yrsno datano data
Toshikazu Kokubun
Director2.1yrsno data0.0075%
$ 95.4k
3.1yrs
Average Tenure
68yo
Average Age

Experienced Board: TWAP.F's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 23:23
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Towa Pharmaceutical Co., Ltd. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Ritsuo WatanabeBofA Global Research
Hidemaru YamaguchiCitigroup Inc